Press "Enter" to skip to content

New York Based Regeneron Pharmaceuticals Inc Reports Crashes 

New York Regeneron Pharmaceuticals Inc shares -0.09% dropped 0.09% to $586.35 Friday. However, this proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.01% rising 1.01% to 4,411.79 and the Dow Jones Industrial Average DJIA, +0.68% rising 0.68% to 35,061.55.

Regeneron Pharmaceuticals Inc. closed $73.65 below its 52-week high ($660.00), which the company achieved on August 5th.The stock crashed when compared to some of its competitors Friday, as Johnson & Johnson JNJ, +1.06% rose 1.06% to $171.79, Novartis AG ADR NVS, +0.54% rose 0.54% to $91.57, and Amgen Inc. AMGN, +1.22% rose 1.22% to $247.72.

Regeneron Pharmaceuticals Inc’s trading volume (628,023) remained 122,297 below its 50-day average volume of 750,320. The stock price of the company is rising 9% over the last twenty-one trading days, while it is down 8% over the last year.

The volatility in the company’s stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. However, over the past few months, we have maintained our view that REGN stock has more room for growth, given the long-term growth potential of some of its drugs, including Eylea and Dupixent. Eylea, an ophthalmology drug, is expected to continue to garner over $7 billion in annual sales for the next few years, while Dupixent, eczema and asthma drug is expected to garner over $12 billion in peak sales. After moving 0.9% or more over ten days, the stock rose in the next ten days on 51% of the occasions

Be First to Comment

Leave a Reply

Your email address will not be published.